THE TGA has approved Yervoy
(ipilimumab) as a monotherapy, for
the treatment of patients with
unresectable (inoperable) or
metastatic melanoma who have
failed or are intolerant to prior
therapy.
The approval follows a global
study of 676 patients with
previously-treated, inoperable or
metastatic melanoma, which found
that around 45% of patients who
were treated with Yervoy
monotherapy were still alive at one
year and more than 20% lived at
least two years.
Speaking about the approval,
Professor Peter Hersey, Research
Director of the Newcastle
Melanoma Unit and Consultant
Immunologist to the Melanoma
Institute Australia said, “It has been
many years since a new therapy for
metastatic melanoma has been
approved in Australia”.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jun 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jun 12
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.